search
Back to results

Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5)

Primary Purpose

Hepatocellular Carcinoma, HCC, Liver Cancer

Status
Unknown status
Phase
Phase 3
Locations
Mongolia
Study Type
Interventional
Intervention
hepcortespenlisimut-L
Placebo
Sponsored by
Immunitor LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Carcinoma focused on measuring AFP, alpha-fetoprotein, cancer vaccine, cirrhosis, hepatitis, HCC, hepatocellular carcinoma, immunotherapy, liver tumor, Cholangiocarcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subjects who are at least 18 years old and are willing and capable of providing informed consent. Both men and non-pregnant women will be included.

HCC diagnosis documented prior to Study Entry by either cytology/histology, CT scan, and AFP serum test higher or equal to 30 IU/ml.

All subjects with reproductive potential are advised to utilize effective contraception throughout the course of this study.

Health score status at baseline. Agreement to participate in the study and to give at least 3 samples of blood for lab tests.

Readily available home or o other address where patient can be found. -

Exclusion Criteria:

Subjects who might have already taken V5 in prior trials and have no baseline data. Those who met inclusion criteria can be retrospectively enrolled. Pregnant or breast-feeding women are excluded.

Subjects who have taken other immunomodulatory therapies within 2 months prior to Entry: systemic corticosteroids, immune globulin (IV gamma globulin, IVIG), interferons, interleukins, pentoxifylline (Trental), thalidomide, filgrastim (G-CSF), sargramostim (GM-CSF); dinitrochlorobenzene (DNCB), thymosin alpha 1 (thymosin alpha), thymopentin, inosiplex (Isoprinosine), polyribonucleoside (Ampligen), ditiocarb sodium (Imuthiol), any locally available immune modulators, and any other therapeutic or preventive HCC vaccine. Subjects requiring concurrent participation in another experimental research treatment study, or who received an experimental agent within four weeks prior to Study Entry.

Evidence of active or acute cardiac disease, epilepsy, or life-threatening diseases unrelated to HCC.

Medical conditions such as active alcohol or substance abuse, or psychological issues that in the opinion of the local investigator would interfere with adherence to the requirements of this study.

-

Sites / Locations

  • Immunitor LLCRecruiting
  • Immunitor LLCRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

hepcortespenlisimut-L

placebo

Arm Description

Experimental placebo-controlled clinical of hepcortespenlisimut-L (V5) therapeutic vaccine against HCC

placebo

Outcomes

Primary Outcome Measures

changes in plasma AFP
Changes in plasma AFP levels at monthly intervals

Secondary Outcome Measures

CT scan
changes in tumor size/mumber at 3 months compared to baseline

Full Information

First Posted
September 3, 2014
Last Updated
February 25, 2019
Sponsor
Immunitor LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT02232490
Brief Title
Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L
Acronym
Hepko-V5
Official Title
Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 2015 (Actual)
Primary Completion Date
November 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Immunitor LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular carcinoma.
Detailed Description
Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular carcinoma. The results will be compared to placebo. The trial duration is 3 months and will consist of one stage with baseline laboratory evaluation including AFP levels with follow-up at monthly intervals. In addition pre-entry abdominal CT scan and end-study CT scan will be preformed. The clinical evaluation will be quantified according to special performance questionnaire.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma, HCC, Liver Cancer
Keywords
AFP, alpha-fetoprotein, cancer vaccine, cirrhosis, hepatitis, HCC, hepatocellular carcinoma, immunotherapy, liver tumor, Cholangiocarcinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
hepcortespenlisimut-L
Arm Type
Experimental
Arm Description
Experimental placebo-controlled clinical of hepcortespenlisimut-L (V5) therapeutic vaccine against HCC
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
placebo
Intervention Type
Biological
Intervention Name(s)
hepcortespenlisimut-L
Other Intervention Name(s)
V5
Intervention Description
hepcortespenlisimut-L (V5) is given in experimental arm
Intervention Type
Biological
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
changes in plasma AFP
Description
Changes in plasma AFP levels at monthly intervals
Time Frame
3 months
Secondary Outcome Measure Information:
Title
CT scan
Description
changes in tumor size/mumber at 3 months compared to baseline
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
adverse effects
Description
evaluation of adverse effects if any
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects who are at least 18 years old and are willing and capable of providing informed consent. Both men and non-pregnant women will be included. HCC diagnosis documented prior to Study Entry by either cytology/histology, CT scan, and AFP serum test higher or equal to 30 IU/ml. All subjects with reproductive potential are advised to utilize effective contraception throughout the course of this study. Health score status at baseline. Agreement to participate in the study and to give at least 3 samples of blood for lab tests. Readily available home or o other address where patient can be found. - Exclusion Criteria: Subjects who might have already taken V5 in prior trials and have no baseline data. Those who met inclusion criteria can be retrospectively enrolled. Pregnant or breast-feeding women are excluded. Subjects who have taken other immunomodulatory therapies within 2 months prior to Entry: systemic corticosteroids, immune globulin (IV gamma globulin, IVIG), interferons, interleukins, pentoxifylline (Trental), thalidomide, filgrastim (G-CSF), sargramostim (GM-CSF); dinitrochlorobenzene (DNCB), thymosin alpha 1 (thymosin alpha), thymopentin, inosiplex (Isoprinosine), polyribonucleoside (Ampligen), ditiocarb sodium (Imuthiol), any locally available immune modulators, and any other therapeutic or preventive HCC vaccine. Subjects requiring concurrent participation in another experimental research treatment study, or who received an experimental agent within four weeks prior to Study Entry. Evidence of active or acute cardiac disease, epilepsy, or life-threatening diseases unrelated to HCC. Medical conditions such as active alcohol or substance abuse, or psychological issues that in the opinion of the local investigator would interfere with adherence to the requirements of this study. -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aldar Bourinbaiar, MD/PhD
Phone
+97695130306
Email
immunitor@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Galyna kutsyna, MD
Phone
9053222
Email
kutsynagalyna@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
aldar bourinbaiar
Organizational Affiliation
Immunitor LLC
Official's Role
Study Director
Facility Information:
Facility Name
Immunitor LLC
City
Ulaanbaatar
ZIP/Postal Code
14400
Country
Mongolia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
aldar Bourinbaiar, MD
Phone
97688094463
Email
immunitor@gmail.com
First Name & Middle Initial & Last Name & Degree
Aldar Bourinbaiar, MD
Email
aldar@immunitor.com
First Name & Middle Initial & Last Name & Degree
Chinburen Jigjidsuren, MD
Facility Name
Immunitor LLC
City
Ulaanbaatar
Country
Mongolia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aldar Bourinbaiar, MD
Phone
97695130306
Email
aldar@immunitor.com
First Name & Middle Initial & Last Name & Degree
Marina Tarakanovskaya, MD
Email
marinatarakanovskaya@yahoo.com
First Name & Middle Initial & Last Name & Degree
Chinburen Jigjidsuren, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
DATA TO BE SHARED WITH COLLABORATORS
Links:
URL
http://www.prweb.com/releases/2014/06/prweb11965485.htm
Description
Interim Phase II trial outcome
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649454/
Description
Phase II results abstract

Learn more about this trial

Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L

We'll reach out to this number within 24 hrs